Comments Regarding “ASBMT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells”

免疫系统
作者
Anne Rain Brown,Cristina Gutiérrez
出处
期刊:Biology of Blood and Marrow Transplantation [Elsevier BV]
卷期号:25 (6): e209-e210 被引量:13
标识
DOI:10.1016/j.bbmt.2019.02.027
摘要

We read with interest the article by Lee et al. [1Lee D.W. Santomasso B.D. Locke F.L. et al.ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells.Biol Blood Marrow Transplant. 2019; 25: 625-638Abstract Full Text Full Text PDF PubMed Scopus (1093) Google Scholar] presenting the updated consensus grading for the management of cytokine release syndrome (CRS) and neurologic toxicity associated with immune effector cells. We applaud experts for gathering to develop consensus grading and welcome unanimity in this new and emerging field given the plethora of published CRS grading systems that emerged with the approval of both tisagenlecleucel and axicabtagene ciloleucel. Authors have noted the importance of streamlining and simplifying toxicity grading to ease implementation across a wide variety of centers [2Gutierrez C. McEvoy C. Mead E. et al.Management of the critically ill adult chimeric antigen receptor-T cell therapy patient: a critical care perspective.Crit Care Med. 2018; 46: 1402-1410Crossref PubMed Scopus (40) Google Scholar, 3Lee D.W. Gardner R. Porter D.L. et al.Current concepts in the diagnosis and management of cytokine release syndrome.Blood. 2014; 124: 188-195Crossref PubMed Scopus (1665) Google Scholar, 4Neelapu S.S. Tummala S. Kebriaei P. et al.Chimeric antigen receptor T-cell therapy—assessment and management of toxicities.Nat Rev Clin Oncol. 2018; 15: 47-62Crossref PubMed Scopus (1235) Google Scholar, 5Porter D. Frey N. Wood P.A. Weng Y. Grupp S.A. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel.J Hematol Oncol. 2018; 11: 35Crossref PubMed Scopus (248) Google Scholar]. New definitions and grading for CRS were reported, namely the elimination of constitutional symptoms (organ toxicity) from grading of CRS. Although the consensus goal was to streamline and simplify the grading system, we believe special attention should be brought to hypotension and vasopressor requirements with grades 3 and 4 CRS. Earlier grading, although more specific, was complicated by the need to calculate vasopressor equivalents, something that brought some difficulty when assessing patients at the bedside [1Lee D.W. Santomasso B.D. Locke F.L. et al.ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells.Biol Blood Marrow Transplant. 2019; 25: 625-638Abstract Full Text Full Text PDF PubMed Scopus (1093) Google Scholar, 3Lee D.W. Gardner R. Porter D.L. et al.Current concepts in the diagnosis and management of cytokine release syndrome.Blood. 2014; 124: 188-195Crossref PubMed Scopus (1665) Google Scholar]. Lee et al. have defined grade 3 hypotension as “requiring a vasopressor with or without vasopressin,” which eases bedside evaluation and grading. However, we believe there are limitations of not making a differentiation between a patient on a low-dose vasopressor and a patient on maximum doses of 2 vasopressors (both grade 3). Critical care data in patients with septic shock suggest that patients requiring a second vasopressor have increased mortality [6Auchet T. Regnier M.A. Girerd N. Levy B. Outcome of patients with septic shock and high-dose vasopressor therapy.Ann Intensive Care. 2017; 7: 43Crossref PubMed Scopus (67) Google Scholar, 7Rhodes A. Evans L.E. Alhazzani W. et al.Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016.Intensive Care Med. 2017; 43: 304-377Crossref PubMed Scopus (3716) Google Scholar, 8Russell J.A. Walley K.R. Singer J. et al.Vasopressin versus norepinephrine infusion in patients with septic shock.N Engl J Med. 2008; 358: 877-887Crossref PubMed Scopus (1225) Google Scholar]. Subgroup analysis has shown a reduction in mortality when vasopressin is applied to patients on norepinephrine to reduce its dosing to less than 15 μg/min [8Russell J.A. Walley K.R. Singer J. et al.Vasopressin versus norepinephrine infusion in patients with septic shock.N Engl J Med. 2008; 358: 877-887Crossref PubMed Scopus (1225) Google Scholar]. This suggest that a “high versus low” dose of norepinephrine can have an effect on mortality, and the severity of shock and dose of vasopressor may directly correlate to severity of illness. Although these data are obtained from patients with septic shock, hypotension secondary to CRS is also a vasodilatory response to inflammation, and such interventions could be extrapolated. With this in mind, however, future studies evaluating the effectiveness of interventions used in the general critically ill population and their effects on the immune effector cells population are necessary. We recognize the authors’ earlier statement noting that “patients who are easily managed with minimal vasopressors are decidedly distinct in terms of CRS severity from those who require high-dose or multiple vasopressors, a key difference accounted for by the grading criteria”; however, concerns could arise that such an observation is not delineated in the grading criteria. Therefore, future efforts in treatment guidelines will hopefully focus on different approaches in treatment on patients on low- versus high-dose vasopressors. Future treatment guidelines should consider increasing corticosteroid dosing on patients with increasing doses of norepinephrine (or first vasopressor of choice at each institution) in an effort to avoid delayed interventions when patients are on high doses of two vasopressors (grade 3) or more than 2 vasopressors (grade 4). Moreover, clinical considerations such as signs of hypoperfusion, organ failure, and increasing lactate levels should also be considered when assessing patient's response to ongoing treatment. In conclusion, the consensus grading is necessary and has simplified significantly the evaluation of these patients at bedside. We do, however, caution the oversimplification of CRS assessment in patients with shock. The omission of vasopressor dose in the grading may lead to under-recognized worsening clinical response. Prompt treatment with global suppression of inflammatory response is imperative in these patients to prevent untimely death, particularly when CRS is usually reversible when treated aggressively and early. Hopefully future treatment guidelines will take this into consideration when managing patients with CRS.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
杜胤江完成签到,获得积分10
刚刚
刚刚
su2589367856完成签到,获得积分10
刚刚
orixero的应助被feiyue126采纳,获得10
刚刚
REBECCA完成签到,获得积分10
刚刚
刚刚
J_Xu完成签到 ,获得积分10
刚刚
yjj发布了新的文献求助20
1秒前
lily发布了新的文献求助10
1秒前
ZZY完成签到,获得积分10
2秒前
爆米花的应助被科研通管家采纳,获得10
2秒前
陈哥完成签到,获得积分10
2秒前
Lucas的应助被科研通管家采纳,获得10
2秒前
顺顺利利的应助被科研通管家采纳,获得10
2秒前
Cyoka完成签到,获得积分10
2秒前
青橙的应助被科研通管家采纳,获得10
2秒前
罗lsz完成签到,获得积分10
2秒前
田様的应助被科研通管家采纳,获得10
2秒前
慢慢完成签到 ,获得积分10
2秒前
NexusExplorer的应助被科研通管家采纳,获得10
2秒前
少女闰土发布了新的文献求助10
3秒前
共享精神的应助被科研通管家采纳,获得10
3秒前
3秒前
可爱滴小花花完成签到,获得积分10
3秒前
秋风的应助被科研通管家采纳,获得10
3秒前
molihuakai的应助被科研通管家采纳,获得10
3秒前
飞飞的应助被科研通管家采纳,获得10
3秒前
方杰完成签到,获得积分10
3秒前
华仔的应助被科研通管家采纳,获得10
3秒前
3秒前
飞飞的应助被科研通管家采纳,获得10
3秒前
秋澄完成签到 ,获得积分10
4秒前
阿钦完成签到,获得积分10
4秒前
skmksd发布了新的文献求助10
4秒前
田様的应助被369ninja采纳,获得10
4秒前
4秒前
Chen完成签到,获得积分10
4秒前
HXX19完成签到,获得积分10
5秒前
Anothermoon完成签到,获得积分10
5秒前
sx完成签到,获得积分10
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180146
求助须知:如何正确求助?哪些是违规求助? 9570319
关于积分的说明 21809739
捐赠科研通 7776294
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039